Low-income rural residents receiving hypertension drugs at no charge had enhanced medication adherence and reduced medical costs in China.
The control rate for hypertension is unacceptably low worldwide, and poor adherence to medication is a primary reason.
To evaluate the impact of full coverage for hypertension drugs on adherence to medication, medical costs, and hypertension control in Shandong Province, China.
In November 2009, we interviewed 110 hypertensive patients who had been participating in a free medication program since May 2008 and 241 hypertensive patients who were not participating. We used a 1:1 propensity-score matching technique to obtain matched samples of 102 program participants (intervention) and 102 nonparticipants (control). We used univariate analysis to compare patient drug-taking behaviors, medical costs, and hypertension control between the 2 groups.
All intervention patients took >1 drugs for hypertension control and 93% of them took >3 such drugs, 15 control patients (15%) did not take any, and only 39% took 3 or more (P <.001). Three-fourths (75%) of the intervention patients took the prescribed drugs regularly, whereas 66% of the control group (P = .034) did so. Participation in the program was associated with lower annual out-of-pocket medical costs both overall and for outpatient services (P <.001 for both).
Low-income rural residents in China receiving free drugs had enhanced medication adherence and reduced total medical costs. Providing hypertension drugs at no charge may be a promising strategy for preventing costly cardiovascular events associated with hypertension in China and other parts of the world with growing rates of cardiovascular disease.
(Am J Manag Care. 2013;19(1):e22-e29)In both developed and developing countries, the control rate for hypertension is unacceptably low, and poor adherence to medication is a primary reason.
Throughout the world, hypertension is the number one attributable risk factor for death, and its prevalence is increasing.1-4 A report for 2001 estimated that worldwide, 14% of deaths and 6% of lost disability-adjusted-life-years were due to hypertension.5 Although the developed countries account for the bulk of economic costs of hypertension, this disorder is responsible for a large and increasing economic and health burden in developing countries, and we can expect that an ever-increasing proportion of the costs is going to be borne by those countries.6,7 For example, it has been predicted that the Asia Pacific region will bear about half of the world’s cardiovascular burden, and high blood pressure is an important determinant of cardiovascular disease.8 In China, the prevalence of hypertension has also been increasing over the past decade and in recent years reached as high as 39% among adults over age 35 years. Not surprisingly, the majority (62%) of strokes and about half (49%) of the cases of ischemic heart disease were attributable to hypertension.9,10 Moreover, morbidity and mortality due to these 2 chronic conditions have been increasing rapidly in China in recent decades.11,12 Given recent trends in cardiovascular disease in China, hypertension control has become a public health priority in that nation.
Fortunately, many effective pharmacologic treatments have become available for outpatient control of high blood pressure. Inpatient care for hypertension and its complications is expensive, but many hospitalizations may be avoided with the use of antihypertensive drugs.13 The challenge is that patient adherence to antihypertensive medications remains poor in both developed and developing countries, and the lack of adherence to prescribed regimens constitutes a barrier to adequate blood pressure control and the prevention of cardiovascular events.14-18 In addition, some researchers have demonstrated that poor adherence to antihypertensive medications is associated with a higher risk of vascular events and hospitalization, and greater healthcare costs.16-18 An increased level of adherence to antihypertensive agents should result in a better health outcome for patients; therefore, providing a medication benefit may be a cost-effective policy option for improving population health.13,17,18 Many researchers have investigated strategies to improve patients’ adherence to medications in a cost-effective manner.19-23
Financial problems such as a lack of health insurance frequently affect patients’ ability to control hypertension because the medications are unaffordable for low-income, rural residents in both developed and developing countries.13,19,23 In 2 US studies, lower copayments for hypertension drugs were associated with improved adherence.20, 22 However, there is limited evidence on the relationship between reducing the cost of hypertension medications and adherence to these medications, although studies have documented the growing problem of hypertension in rural China.24-26 To fill in this gap, we evaluated the effectiveness of a medication subsidy program in rural communities in Shandong Province, China, by conducting and analyzing a face-to-face interview survey of hypertensive patients. The effectiveness was measured by patients’ medication adherence status, economic burden of disease, and blood pressure levels.
BACKGROUND OF THE MEDICATION SUBSIDY PROGRAM
In 2007, the health department of Shandong Province developed an initiative, Rural Health Care Workers Training and Non-communicable Disease Control Programs, which was supported by the government of Luxembourg through collaborations with the World Health Organization. The initiative focused primarily on (1) training rural healthcare workers in chronic disease control and prevention and (2) improving rural residents’ awareness of health risk factors and promoting a healthy lifestyle. Eight rural counties were selected to be the project counties. A baseline survey, which elicited information from families and also included a medical examination and laboratory testing, was conducted in the project counties from April 13 to May 1, 2007. This survey revealed that many patients with hypertension did not know the adverse health impacts of high blood pressure, and even if they had hypertension, they were not taking any antihypertensive drugs. These patients were more likely to have a low income and less likely to be able to afford antihypertensive drugs or obtain standard treatment. Overall, the rates of hypertension treatment and control were unacceptably low; thus, a program to subsidize the cost of medication was implemented in May 2008 in selected villages of all 8 counties.
DETAILS OF THE PROGRAM
The subsidy program provided basic medicines at no charge for hypertensive patients in low-income families, as well as standard treatment and management as needed. The basic medication regimen, the NAH (nifedipine, atenolol, hydrochlorothiazide) program, was recommended by the China National Hypertension League. More generally, the program had 3 components: (1) At the initial clinic visit, the patient received a standard dose of medication according to blood pressure level, age, and sex (eg, nifedipine 2.5 mg 3 times daily, atenolol 6.25 mg once daily, or hydrochlorothiazide 6.25 mg once daily). The patient was asked to have a follow-up visit in 3 to 5 days. (2) At follow-up, the drug regimen was adjusted if needed according to blood pressure control status and drug complications. (3) If the 3 drugs could not bring the blood pressure under control, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, angiotensin II receptor blockers, and other drugs were added as appropriate. The patients received the hypertension drugs at no charge from the clinicians, and the clinicians were reimbursed 150 Chinese yuan per year for every patient served by the Rural Healthcare Workers Training and Non-communicable Disease Control Programs. (The 150 yuan was usually enough to cover the costs of hypertension drugs for each patient for a year in the rural communities.) The 3 main outcomes of interest were patient’s medication adherence status, the economic burden of disease, and the blood pressure level. Medication adherence was determined by observing the patient’s medication-taking behavior. The patient’s economic burden of disease was total medical costs of chronic diseases associated with hypertension, including inpatient, outpatient, and medication costs.
In November 2009, about 18 months after the subsidy program began, a field survey in 2 townships in Cangshan County, 1 of the intervention counties, was conducted by trained researchers and graduate students from School of Public Health, Shandong University. In both townships, 2 villages were randomly selected as the project intervention sites. All hypertensive patients living in the villages were included. The survey involved holding face-to-face interviews with 110 hypertensive patients who received free hypertension drugs in the 4 villages (the intervention group) and 241 hypertensive patients of similar economic status who did not participate in the free medication program in 7 adjacent villages (the control group). A predesigned questionnaire covered major sociodemographic variables, number of family members with high blood pressure, health complications, time since diagnosis, knowledge about hypertension, behaviors (following the doctor’s advice and taking medication), and inpatient and outpatient medical expenses. The survey was designed to evaluate the effectiveness of a medication subsidy for low-income rural patients with noncommunicable diseases. The survey contained 15 forms that were developed and pilot-tested by a research team at Shandong University. We only analyzed the survey items related to hypertension ().
Blood pressure measurements were obtained from clinic technician records from 2009 (a year after the subsidy program began). Both systolic and diastolic blood pressures were measured twice in a 3- to 5-day interval. If either the systolic or diastolic measure differed by 6 or more mm Hg between the 2 measurements, a third measurement was taken. The average of the 2 or 3 measurements was recorded as the blood pressure level. Medical cost was collected from health insurance agencies and confirmed or supplemented by the face-toface interview.
We used a 1:1 propensity-score matching technique to obtain patients for the intervention and control groups based on the information from our survey.27-30 Because the intervention and control groups were not randomly selected, the distribution of characteristics among patients in the intervention group was quite different from that among patients in the control group, although we tried to select the patients with similar economic status in both groups (). It was possible that the distribution of their demographic characteristics (eg, age, sex, education) or of other factors could have biased our results when we compared the 2 groups. Thus, to minimize the potential bias in the analysis, we derived the matched samples using a logistic regression model based on patients’ age, sex, education, marital status, economic status, health status, and insurance participation.27 Then, using the matched sample populations, we compared medication-taking behavior, medical costs, and blood pressure control status.
We used the χ2 test for categorical variables and the Wilcoxon 2-sample test for continuous variables. All tests of statistical significance were 2-tailed, and because our study samples were small, we considered P <.05 to indicate a significant difference. The SAS statistical package (Version 9.1, SAS, Cary, North Carolina) was used for all of the analyses.
Before the propensity-score matching, 5 variables were found to differ significantly by group (Table 1): education, per capita income, health complications, time since patient was first diagnosed with hypertension, and knowledge of the relationship between hypertension and diet. These differences, if left uncorrected, would have biased the comparison analysis of medication-taking behaviors, medical costs, and blood pressure levels. After propensity-score matching, the 5 significant distribution differences in the population characteristics (Table 1) were greatly reduced, and only 1 of these characteristics, health complications (P <.05), differed significantly between the intervention and control groups (). Thus, the 2 groups were now comparable and could be used for the comparison analysis.
Patients who received a medication subsidy were more likely to take some prescribed drugs for hypertension control than were unsubsidized patients (P <.001;). In the intervention group, every patient took at least 1 prescribed drug for hypertension and 93.1% took 3 or more such drugs. In contrast, 14.7% of control group patients took no prescribed hypertension drugs at all and only 39.2% took 3 or more of these drugs.
In the intervention group, the percentage of patients who always took a prescribed hypertension drug and the percentage who took such drugs most of the time were higher than they were in the control group, but the difference in the overall pattern (taking medication regularly) was only significant at the P <.05 level (P = .034). For patients who did not regularly take a blood pressure medication, the main reason in both groups was “not feeling sick” followed by “forgetting.” The samples here were much smaller than for the other 2 items, and the overall difference between the intervention and control groups was not statistically significant (P = .782).
Annual out-of-pocket medical costs (including inpatient, outpatient, and medications) were significantly lower for patients in the intervention group than for those in the control group (575 Chinese yuan vs 688 yuan; P <.001) (). In addition, the median for total out-of-pocket costs was far lower for patients receiving the subsidy (120 yuan vs 228 yuan). The difference in out-of-pocket costs for outpatient visits, including medications, was significant (192 yuan vs 380 yuan; P <.001). Finally, the out-of-pocket costs as a percentage of family income were much lower for patients receiving the subsidy (12.3% vs 27.7%; P <.001).
Both systolic and diastolic blood pressures were not significantly lower for patients in the intervention group compared with the control group (P = .379 and P = .544, respectively) (). Similarly, the proportion of patients with their hypertension under control was not significantly different between the intervention and control groups (P = .831).
By developing statistically similar samples for intervention and control groups using the propensity-score matching technique, we were able to estimate the effects of a drug subsidy program by comparing the outcomes of the 2 groups at a single time point. In that way, our study is different from other studies, which usually estimate a program’s effect by comparing data from before and after the intervention.31,32 Further, our use of the propensity-score matching method was only one of the analysis’s strengths. For example, our study may be the first to investigate the effect on hypertension control in China of providing financial incentives directly to patients. Our results suggest that the subsidy increased medication adherence, which is consistent with evidence from abroad.13,20,22 Moreover, although blood pressure measurements were not significantly lower for patients in the intervention group compared with patients in the control group, they were much lower than the blood pressure measurements before the intervention (in 2007). Thus, policy makers in China should consider subsidizing necessary drugs when they are developing hypertension control policies.
Another strength is that we collected information not only on medication-taking behavior, but also on relevant variables such as socioeconomic status, medical costs, and health status. Thus, the survey instrument we used might be useful for investigating the impacts of other health intervention programs such as initiatives to reduce sodium intake or to prevent stroke and diabetes, all of which are significant public health issues in today’s China. “Not feeling sick” was the main reason for not regularly taking the medication in both the intervention and the control groups, which may suggest a need for further patient education. Finally, our results suggest that the medication subsidy reduced the total economic burden of chronic diseases for the patients, which is consistent with findings in developed countries.17,18,20,22,33,34 This suggests a solid economic return from the intervention.
Its strengths notwithstanding, our study had several limitations that may limit its application to other settings. First, because the funding for our research was limited, we could interview only a small number of patients in the intervention and control villages for the evaluation. The relatively small sample might help to explain why some of our results were not statistically significant. Second, also because of our small sample, we conducted only univariate analyses; thus, we could not examine the effect of potential confounders on the program’s impact. Correspondingly, we did not know how much of the difference in medication-taking behaviors and medical costs between the intervention and control groups was actually attributable to the subsidy program. More data and approaches using advanced econometric models would be required for such an evaluation. Finally, our evaluation period was too short to investigate the program’s linkage to the incidence of health complications such as heart attack and stroke. We should also note that although patients’ adherence to medication increased, their blood pressure levels did not decrease significantly. This might be in part because our sample was too small or because there was insufficient intensification of medications. Further investigation on the impact of a drug subsidy on blood pressure levels and associated complications such as heart attack and stroke should be carried out in the future.
Our evaluation of a subsidy program focused on prescribed hypertension drugs indicates that it improved patients’ adherence to taking such medication and reduced their financial burden in several different ways. Because poor adherence to medication regimens is common and the cost of medication is a major predictor of poor adherence,21,22,35-37 subsidizing the costs of hypertension drugs may be a cost-effective policy option if it can reduce the complications of hypertension, prevent a large number of deaths, and contain the growing healthcare costs through a reduction in blood pressure. However, more economic research is needed to produce the evidence that such an intervention would be cost-effective in both developed and developing countries.
The conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Author Affiliations: From School of Insurance and Economics (BY), University of International Business and Economics, Chaoyang, Beijing, China; The Institute of Medical Information (XZ), Chinese Academy of Medical Science, Chaoyang District, Beijing, China; Division for Heart Disease and Stroke Prevention (GW), Centers for Disease Control and Prevention, Atlanta, GA.
Funding Source: None.
Author Disclosures: The authors (BY, XZ, GW) report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.
Authorship Information: Concept and design (BY, GW); acquisition of data (BY, XZ); analysis and interpretation of data (BY, XZ, GW); drafting of the manuscript (BY, XZ, GW); critical revision of the manuscript for important intellectual content (BY, GW); statistical analysis (XZ, GW); administrative, technical, or logistic support (GW).
Address correspondence to: Guijing Wang, PhD, Division for Heart Disease and Stroke Prevention, Centers for Disease Control and Prevention, 4770 Buford Hwy, Atlanta, GA 30341. E-mail: email@example.com. World Health Organization. The world health report 2002—Reducing Risks, Promoting Healthy Life. Geneva, Switzerland. http://www.who. int/whr/2002/en/index.html. Published 2002. Accessed July 22, 2012.
2. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-223.
3. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21(11):1983-1992.
4. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997;349(9063): 1436-1442.
5. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513-1518.
6. Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff (Millwood). 2007;26(1):13-24.
7. Gaziano TA, Bitton A, Anand S, Weinstein MC; International Society of Hypertension. The global cost of nonoptimal blood pressure. J Hypertens. 2009;27(7):1472-1477.
8. Lawes CM, Rodgers A, Bennett DA, et al; Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21(4):707-716.
9. Gu D, Reynolds K, Wu X, et al; InterASIA Collaborative Group. The International Collaborative Study of Cardiovascular Disease in ASIA. Prevalence, awareness, treatment, and control of hypertension in China. Hypertension. 2002;40(6):920-927.
10. Meng XJ, Dong GH, Wang D, et al. Prevalence, awareness, treatment, control, and risk factors associated with hypertension in urban adults from 33 communities of China: the CHPSNE study. J Hypertens. 2011;29(7):1303-1310.
11. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124-1134.
12. Yang G. Chronic diseases in China: challenges and countermeasures. 2007 Shanghai International Symposium on Public Health. 2007:8-9. December 11-14, 2007. Shanghai, China.
13. Wagner AK, Valera M, Graves AJ, Laviña S, Ross-Degnan D. Costs of hospital care for hypertension in an insured population without an outpatient medicines benefit: an observational study in the Philippines. BMC Health Serv Res. 2008;8:161.
14. Waeber B, Burnier M, Brunner HR. How to improve adherence with prescribed treatment in hypertensive patients? J Cardiovasc Pharmacol. 2000;35(suppl 3):S23-S26.
15. Hawkshead J, Krousel-Wood MA. Techniques for measuring medication adherence in hypertensive patients in outpatient settings: advantages and limitations. Dis Manag Health Outcomes. 2007;15: 109-118.
16. Chapman RH, Ferrufino CP, Kowal SL, Classi P, Robert CS. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs. Int J Clin Pract. 2010;64(2):169-281.
17. Dragomir A, Côté R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48(5):418-425.
18. Pittman DG, Tao Z, Chen W, Stettin GD. Antihypertensive medication adherence and subsequent healthcare utilization and costs. Am J Manag Care. 2010;16(8):568-576.
19. Martin MY, Kohlor C, Kim YI, et al. Taking less than prescribed: medication nonadherence and provider-patient relationships in lowerincome, rural minority adults with hypertension. J Clin Hypertens (Greenwich). 2010;12(9):706-713.
20. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Medication adherence and use of generic drug therapies. Am J Manag Care. 2009;15(7):450-456.
21. Rabbani A, Alexander GC. Out-of-pocket and total costs of fixeddose combination antihypertensive and their components. Am J Hypertens. 2008;21(5):509-513.
22. Gibson TB, Mark TL, Axelsen K, Baser O, Rubler DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12(Spec. no):P11-P19.
23. Cook S, Drum ML, Kirchhoff AC, et al. Providers’ assessment of barriers to effective management of hypertension and hyperlipidemia in community health centers. J Health Care Poor Underserved. 2006; 17(1):70-85.
24. Li H, Meng Q, Sun X, Salter A, Briggs NE, Hiller JE. Prevalence, awareness, treatment, and control of hypertension in rural China: results from Shandong province. J Hypertens. 2010;28(3):432-438.
25. Sun Z, Zheng L, Detrano R, et al. Incidence and predictors of hypertension among rural Chinese adults: results from Liaoning Province. Ann Fam Med. 2010;8(1):19-24.
26. Sun Z, Zheng L, Wei Y, et al. The prevalence of prehypertension and hypertension among rural adults in Liaoning province of China. Clin Cardiol. 2007;30(4):183-187.
27. D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281.
28. Ahmed A, Rich MW, Sanders PW, et al. Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study. Am J Cardiol. 2007;99(3):393-398.
29. Ekundayo OJ, Allman RM, Sanders PW, et al. Isolated systolic hypertension and incident heart failure in older adults: a propensitymatched study. Hypertension. 2009;53(3):458-465.
30. Wang G, Zhang Z, Ayala C. Hospitalization costs associated with hypertension as a secondary diagnosis among insured patients aged 18-64 years. Am J Hypertens. 2010;23(3):275-281.
31. Gan J, Gao Y, Yan Y, Yang X, Li S, Zhang X. Evaluation of the effects of rural community stations on comprehensive intervention for patients with hypertension [in Chinese]. Chinese J Clinicians. 2009;39(11): 48-50.
32. Liu L. Evaluation of community interventions: case studies of 415 patients with hypertension [in Chinese]. China Practical Med. 2009;4(28):256-257.
33. Muszbek N, Brixner D, Benedict A, Keskinaslan A, Khan ZM. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review. Int J Clin Pract. 2008;62(2):338-351.
34. Choudhry NK, Avorn J, Glynn RJ, et al; Post-Myocardial Infarction Free Rx Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088-2097.
35. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
36. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638-645.
37. Wiegand P, McCombs JS, Wang JJ. Factors of hyperlipidemia medication adherence in a nationwide health plan. Am J Manag Care. 2012;18(4):193-199.